TAKE A LOOK AT WHICH REPORT YOUR PORTFOLIO'S BEEN MISSING...

Shareholders Foundation offers real-time reporting of class action exposure on a per transaction basis,
including the documents you will need for claim filing and settlement recovery.
Start Monitoring Your Investments

Tetraphase Pharmaceuticals Inc (NASDAQ: TTPH) Investor Securities Class Action Lawsuit 01/28/2016

  • If you purchased shares of Tetraphase Pharmaceuticals Inc (NASDAQ: TTPH), you may have certain options. Please contact the Shareholders Foundation, Inc.

  • To have your information reviewed for options and to receive notifications about this case, please send an email to mail@shareholdersfoundation.com, or call us at (858) 779-1554.

Lawsuit Overview

Case Dismissed
Company
Tetraphase Pharmaceuticals Inc
Security
NASDAQ: TTPH

Case Name
Tetraphase Pharmaceuticals Shareholder Class Action Lawsuit 01/28/2016
Type of Lawsuit
Shareholder Class Action
Court of Filing
U.S. District Court for the District of Massachusetts

Class Period Begin
Class Period End
Deadline To File for Lead
You must register or login to receive notifications.

Click here to subscribe to Tetraphase Pharmaceuticals Inc.
Summary

December 11, 2017 - The U.S. Court of Appeals for the First Circuit ordered that this appeal be voluntarily dismissed.

May 19, 2017 - The lead plaintiff filed a notice of appeal.

May 9, 2017 - The court granted defendants' motion to dismiss.

October 11, 2016 - A motion to dismiss the second amended complaint was filed.

August 25, 2016 - A second amended complaint was filed.

July 25, 2016 - An amended complaint was filed.

January 28, 2016 - An investor in shares of Tetraphase Pharmaceuticals Inc (NASDAQ: TTPH) filed a lawsuit in the U.S. District Court for the District of Massachusetts over alleged violations of Federal Securities Laws by Tetraphase Pharmaceuticals Inc in connection with certain allegedly false and misleading statements made between March 5, 2015 and September 8, 2015.

According to the complaint the plaintiff alleges on behalf of purchasers of Tetraphase Pharmaceuticals Inc (NASDAQ: TTPH) common shares between March 5, 2015 and September 8, 2015, that the defendants violated Federal Securities Laws. More specifically, the plaintiff claims that between March 5, 2015 and September 8, 2015 Tetraphase Pharmaceuticals Inc made allegedly positive statements about the efficacy and potential for its drug Eravacycline to achieve approval by the FDA, despite knowledge that a pivotal portion of its IGNITE2 phase 3 clinical trial for Eravacycline would fail to achieve its primary endpoint of statistical non-inferiority compared to the antibiotic Levofloxacin.

Tetraphase Pharmaceuticals Inc reported that its annual Total Revenue declined from $10.49 million in 2013 to $9.10 million in 2014 and that its respective Net Loss increased from $29.64 million to $66.74 million. Shares of Tetraphase Pharmaceuticals Inc (NASDAQ: TTPH) grew from $8.83 per share in May 2014 to as high as $51.75 per share in July 2015.

On September 8, 2015, Tetraphase Pharmaceuticals Inc (NASDAQ: TTPH) announced that the IGNITE2 phase 3 clinical trial of eravacycline administered as an IV to oral transition therapy for the treatment of complicated urinary tract infections (cUTI) did not achieve its primary endpoint of statistical non-inferiority compared to levofloxacin. Shares of Tetraphase Pharmaceuticals Inc (NASDAQ: TTPH) declined to as low as $9.06 per share on September 9, 2015.